{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:15:11Z","timestamp":1788023711327,"version":"build-2784847793"},"reference-count":41,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Samsung Bioepis Co., Ltd"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1080\/14712598.2021.1958778","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T17:17:16Z","timestamp":1627406236000},"page":"203-223","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence"],"prefix":"10.1080","volume":"22","author":[{"given":"Fabio Salvatore","family":"Macaluso","sequence":"first","affiliation":[{"name":"Gastroenterologist, Inflammatory Bowel Disease Unit, \u201cVilla Sofia-Cervello\u201d Hospital, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9659-3247","authenticated-orcid":false,"given":"JR Fraser","family":"Cummings","sequence":"additional","affiliation":[{"name":"Gastroenterologist, Department of Gastroenterology, University Hospital Southampton, and University of Southampton, Southampton, Hampshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Atreya","sequence":"additional","affiliation":[{"name":"Gastroenterologist, Department of Medicine, Medical Clinic 1, University Hospital Erlangen, University of Erlangen-N\u00fcrnberg Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeyun","family":"Choi","sequence":"additional","affiliation":[{"name":"Manager, Medical Affairs Group, Yeonsu-gu, Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambrogio","family":"Orlando","sequence":"additional","affiliation":[{"name":"Gastroenterologist, Inflammatory Bowel Disease Unit, \u201cVilla Sofia-Cervello\u201d Hospital, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,2,18]]},"reference":[{"key":"e_1_3_5_3_1","volume-title":"Remicade - Summary of Product Characteristics","author":"Janssen Biologics","year":"1999","unstructured":"Janssen Biologics. Remicade - Summary of Product Characteristics. 1999. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remicade-epar-product-information_en.pdf"},{"key":"e_1_3_5_4_1","volume-title":"Remicade - Prescribing Information","author":"Janssen Biotech","year":"1998","unstructured":"Janssen Biotech. Remicade - Prescribing Information. 1998. Available from: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/REMICADE-pi.pdf"},{"key":"e_1_3_5_5_1","unstructured":"US Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product 2015 [2020 Mar 24]. Available from: https:\/\/www.fda.gov\/media\/82647\/download"},{"key":"e_1_3_5_6_1","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies \u2013 non-clinical and clinical issues 2012 [2020 Mar 24]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf"},{"key":"e_1_3_5_7_1","unstructured":"European Medicines Agency. Biosimilars in the EU - Information guide for healthcare professionals [March 24 2020]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf"},{"key":"e_1_3_5_8_1","unstructured":"US Food and Drug Administration. Biosimilar Development Review and Approval [April 2020]. Available from: https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-development-review-and-approval"},{"key":"e_1_3_5_9_1","doi-asserted-by":"crossref","unstructured":"Khan N Patel D Pernes T et al. The Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients. Crohn\u2019s & Colitis 360. 2021;3:2","DOI":"10.1093\/crocol\/otab022"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756284820982802"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201800340"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00402-0"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1264550"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2016-001085"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2017.1337620"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0150-5"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207764"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex254"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211741"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz203.765"},{"key":"e_1_3_5_21_1","volume-title":"P1135 - Therapeutic drug monitoring supports clinical decision making when employed before and after biosimilar infliximab switching","author":"Haggarty R","year":"2019","unstructured":"Haggarty R, Waddell K, Veryan J, et al. P1135 - Therapeutic drug monitoring supports clinical decision making when employed before and after biosimilar infliximab switching. Barcelona: Therapeutic Drug Monitoring; 2019."},{"issue":"8","key":"e_1_3_5_22_1","first-page":"361","article-title":"IBD biosimilar to biosimilar infliximab switching study: preliminary results","volume":"7","author":"Harris C","year":"2019","unstructured":"Harris C, Harris R, Young D, et al. IBD biosimilar to biosimilar infliximab switching study: preliminary results. United European Gastroenterol J. 2019;7(8):361.","journal-title":"United European Gastroenterol J"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(19)30462-1"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz203.614"},{"key":"e_1_3_5_25_1","article-title":"The SPOSIB SB2 Sicilian Cohort: safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches","author":"Macaluso FS","year":"2020","unstructured":"Macaluso FS, Fries W, Viola A, et al. The SPOSIB SB2 Sicilian Cohort: safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches. Inflamm Bowel Dis. 2020;27(2):182-189.","journal-title":"Inflamm Bowel Dis"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz203.489"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.02.007"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.4388"},{"issue":"1","key":"e_1_3_5_29_1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/annrheumdis-2020-eular.5682","article-title":"THU0164 PERFUSE: a french prospective\/retrospective non-interventional cohort study of infliximab-naiive and transitioned patients receiving infliximab biosimilar SB2; an interim analysis","volume":"79","author":"Fautrel B","year":"2020","unstructured":"Fautrel B, Bouhnik Y, Desjeux G, et al. THU0164 PERFUSE: a french prospective\/retrospective non-interventional cohort study of infliximab-naiive and transitioned patients receiving infliximab biosimilar SB2; an interim analysis. Ann Rheum Dis. 2020;79(Suppl 1):297\u2013298.","journal-title":"Ann Rheum Dis"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19013"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy222.678"},{"key":"e_1_3_5_32_1","volume-title":"P-108 - Therapeutic Drug Monitoring of the Biosimilar SB2 (RENFLEXIS\u2122, Infliximab-abda) Using LabCorp Infl iximab Assays for Drug Level and Anti-drug Antibodies","author":"Chun K","year":"2017","unstructured":"Chun K, Garcia Gonzalez Z, Yang J. P-108 - Therapeutic Drug Monitoring of the Biosimilar SB2 (RENFLEXIS\u2122, Infliximab-abda) Using LabCorp Infl iximab Assays for Drug Level and Anti-drug Antibodies. 2017."},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izx086"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000565"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756284818796956"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2020.01.006"},{"key":"e_1_3_5_37_1","first-page":"112:S398","article-title":"Abstract 722 - Infliximab Assay Used in Clinical Practice Validated for Measuring SB2 Infliximab Biosimilar\u2019s Serum Drug and Anti-drug Antibody Levels","author":"Noguier G","year":"2017","unstructured":"Noguier G, Davi\u00e8re S, Elouardani S, et al. Abstract 722 - Infliximab Assay Used in Clinical Practice Validated for Measuring SB2 Infliximab Biosimilar\u2019s Serum Drug and Anti-drug Antibody Levels. Am J Gastroenterol. 2017;112:S398.","journal-title":"Am J Gastroenterol"},{"key":"e_1_3_5_38_1","volume-title":"Flixabi - Summary of Product Characteristics","author":"Samsung Bioepis","year":"2016","unstructured":"Samsung Bioepis. Flixabi - Summary of Product Characteristics. 2016."},{"key":"e_1_3_5_39_1","volume-title":"Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product - Guidance for Industry","author":"US Food and Drug Administration","year":"2016","unstructured":"US Food and Drug Administration. Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product - Guidance for Industry. 2016."},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.06.016"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208684"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14089"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-017-0085-z"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2021.1958778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T05:15:05Z","timestamp":1721625305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2021.1958778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1080\/14712598.2021.1958778"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2021.1958778","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}